ModifiedCentenePolicy CP MP.69

Intensity-Modulated Radiotherapy

Medical necessity criteria and coding implications for IMRT for non-Medicare Centene-affiliated health plans; describes covered indications, background, and referenced codes and guidance.

Policy Summary

PayerCentene

PolicyIntensity-Modulated Radiotherapy

Policy CodePolicy CP MP.69

Change TypeMaterial revisions with additions and removals to coverage criteria

Effective Date

Next Review Date

Key ActionObtain prior authorization per plan rules for IMRT services and verify the Health Plan-specific effective date and applicable authorization requirements before delivering treatment.

SourceLink

POLICY UPDATE CHANGES

Added Criteria I.G.9. uterine neoplasms and added Criteria lung cancer.

Removed I.G.8.a.i-iii regarding maximum dose volume and other breast-specific volume/hot spot criteria, leaving homogeneity language and changed internal mammary lymph node wording; updated APBI wording.

Added non-Medicare health plan note and referral to MC.CP MP.69 for Medicare plans.

multiplelisted anatomic/site indications for IMRT

4 codesCPT/HCPCS groups listed

2 G-codesG-codes included

through 04/24 & 02/25revision log entries

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for IMRT

Covered Indications

IMRT is medically necessary for non-Medicare Centene-affiliated health plan members when ANY of the following indications are met:

Age: Patients < 18 years with a solid tumor

policy I.A

Medically inoperable disease: Medically inoperable patient with diagnosis of cancer where dose escalation is required

policy I.B

Re-irradiation where cumulative critical structure dose would exceed tolerance dose

policy I.D

Primary bone tumors: Primary malignant or benign bone tumors

policy I.C

Central nervous system and spine: CNS tumors, tumors at or approaching the skull base; craniospinal irradiation; primary CNS or spine tumors, or metastatic tumors to the spine/spinal cord where organ-at-risk tolerance may be exceeded with 3-D conformal treatments

policy I.E.1-1.c

Hippocampal-sparing WBRT: Brain metastases requiring hippocampal-sparing whole brain radiotherapy

policy I.E.1.e

Head and neck: Definitive, adjuvant, or palliative treatment of primary or secondary head and neck cancers or draining lymphatics (including nasopharynx, nasal cavity, paranasal sinuses, oropharynx, oral cavity, hypopharynx, larynx, thyroid, salivary glands), plus cutaneous tumors with cranial nerve invasion, mucosal melanoma, and occult primary head and neck malignancies

policy I.E.2 and subitems

Breast: Bilateral breast cancers requiring nodal treatment on at least one side; definitive treatment when unfavorable anatomy would deliver unacceptably high OAR doses (e.g., pectus excavatum); accelerated partial breast irradiation (APBI); early-stage disease when heart dose is unacceptably high with conventional techniques; internal mammary node targeting; post-mastectomy with bilateral implant-based reconstruction; limited ipsilateral arm range of motion requiring arms-down positioning; whole breast with bilateral augmentation implants

policy I.G and revision notes

Thoracic: Primary or secondary mediastinal tumors (including thymic tumors, mediastinal lymphomas, thoracic sarcomas); early-stage lung cancer when SBRT is not feasible due to anatomy; locally advanced disease where IMRT significantly reduces dose to normal tissues (examples: bilateral mediastinal disease, paraspinal tumors, N3 disease, reducing esophageal dose)

policy Thoracic indications

Gastrointestinal: Esophageal and gastroesophageal junction cancers; malignant pleural mesothelioma; hepatocellular, bile duct, gallbladder and cholangiocarcinoma; primary and secondary liver cancers; primary pancreatic, gastric and adrenal cancers

policy I.5 subitems

Sarcomas: Retroperitoneal sarcomas, desmoid tumors, and soft tissue sarcomas where organ-at-risk constraints cannot be met with conventional techniques

policy I.6 and subitems

Genitourinary and gynecologic: Prostate, renal, bladder, penile, ureteral cancers; cervical, endometrial, vulvar and vaginal cancers; uterine neoplasms (added in revisions)

policy I.G and revision history

Anal and rectal: Anal and select rectal cancer cases where lymph node involvement or inguinal node treatment is required

policy I.6 and later edits

Other site-specific indications: Ocular tumors including intraocular melanomas; cutaneous tumors with cranial nerve invasion; mucosal melanoma; occult primary head and neck; mediastinal lymphomas and thymomas; and other listed subsites where IMRT is commonly performed

various subsite listings

This clinical policy governs IMRT medical necessity determinations for non‑Medicare Centene‑affiliated health plans. For criteria that apply to Medicare members, please refer to the Medicare‑specific policy MC.CP MP.69 Intensity‑Modulated Radiotherapy as noted in the policy guidance; Medicare criteria supersede this document for Medicare members.

When coverage provisions in a state Medicaid program conflict with this clinical policy, the state Medicaid coverage provisions take precedence. Providers should consult the applicable state Medicaid manual for specific coverage rules and follow any state‑level requirements that differ from this clinical policy.

Prior breast‑specific criteria that set maximum dose‑volume and 'hot‑spot' limits (e.g., maximum dose volume for breast tissue and hot spots in the inframammary fold) have been removed from this clinical policy. The policy no longer applies those prior numeric dose‑volume/hot‑spot criteria; retained language addresses dose homogeneity and other breast‑specific indications as updated in the revision history.

Coding and Billing References

Referenced CPT CodesCPT

77301	Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications
77338	Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT) design and construction per IMRT plan
77385	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking when performed; simple
77386	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking when performed; complex

Referenced HCPCS/G CodesHCPCS

G6015	Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session
G6016	Compensator-based beam modulation treatment delivery of inverse planned treatment using three or more high resolution (milled or cast) compensator; convergent beam modulated fields, per treatment session

Provider Actions and Documentation Requirements

Prior Authorization

Verify effective date and authorizations

Verify the effective date of this clinical policy and confirm prior authorization requirements and any plan- or state-specific authorizations before scheduling IMRT services. Authorization requirements and effective dates may differ by Health Plan; when conflicts exist between this clinical policy and legal/regulatory requirements, law governs.

Confirm member eligibility and benefit terms (EOC/policy/certificate) prior to service.
Obtain prior authorization when required by the Health Plan; do not rely on the posting date as the effective date.

Documentation Required

Planning and documentation

IMRT planning is a multi-step process that requires complete documentation of target and normal-structure contouring and dose–volume relationships. Include planning records such as the IMRT plan (CPT 77301), dose-volume histograms, organ-at-risk contours, and rationale for IMRT versus other techniques when clinical necessity depends on proximity to critical structures or potential dose escalation.

Background on IMRT

Intensity‑modulated radiotherapy (IMRT) is an external‑beam radiation technique that delivers highly conformal doses by varying radiation intensity across treatment fields. IMRT planning is a multi‑step process that includes contouring targets and critical structures to minimize dose to nearby sensitive normal tissues. The technology is used when precise dose sculpting is needed to escalate tumor dose while reducing exposure to organs at risk.

Definitions and Policy Terms

Intensity-modulated radiotherapy — definition entry for IMRT

TermIntensity-modulated radiotherapy (IMRT)

DefinitionA technology that delivers highly conformal external beam radiation to specified targets using beams whose intensity varies throughout the treatment fields.

Clinical rationaleUseful for delivering highly conformal doses to targets adjacent to sensitive normal tissues; planning is a multi-step process that includes contouring to define targets and avoid normal structures.

ConsiderationsThe technique can introduce dose inhomogeneity and requires additional planning and QA time; may expose larger normal tissue volumes to lower doses.

Clinical policy — definition of clinical policy as guide to medical necessity, not a contract

Purpose